Review: taking Neurontin and Intuniv together


Summary

Drug interactions are reported among people who take Neurontin and Intuniv together. This review analyzes the effectiveness and drug interactions between Neurontin and Intuniv. It is created by eHealthMe based on reports of 123 people who take the same drugs from FDA and social media, and is updated regularly.

Personalized health information

On eHealthMe you can find out what patients like me (same gender, age) reported their drugs and conditions on FDA and social media since 1977. Our tools are free and anonymous. 86 million people have used us. 300+ peer-reviewed medical journals have referenced our original studies. Start now >>>


Neurontin

Neurontin has active ingredients of gabapentin. It is often used in pain. (latest outcomes from Neurontin 76,477 users)

Intuniv

Intuniv has active ingredients of guanfacine hydrochloride. It is often used in attention deficit hyperactivity disorder. (latest outcomes from Intuniv 1,613 users)

On Sep, 17, 2016

123 people who take Neurontin, Intuniv are studied.


Number of reports submitted per year:

Neurontin and Intuniv drug interactions.

Drug effectiveness over time:

Neurontin:
  • < 1 month: 0.0% - (0 of 0 people)
  • 1 - 6 months: 100.0% - (1 of 1 people)
  • 6 - 12 months: 0.0% - (0 of 0 people)
  • 1 - 2 years: 100.0% - (1 of 1 people)
  • 2 - 5 years: 100.0% - (3 of 3 people)
  • 5 - 10 years: 0.0% - (0 of 1 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)
Intuniv:
  • < 1 month: 0.0% - (0 of 2 people)
  • 1 - 6 months: 50.0% - (1 of 2 people)
  • 6 - 12 months: 0.0% - (0 of 1 people)
  • 1 - 2 years: 0.0% - (0 of 1 people)
  • 2 - 5 years: 100.0% - (1 of 1 people)
  • 5 - 10 years: 0.0% - (0 of 0 people)
  • 10+ years: 0.0% - (0 of 0 people)
  • not specified: 0.0% - (0 of 0 people)

Drug effectiveness by gender:

Neurontin:
  • female: 100.0% - (2 of 2 people)
  • male: 75.0% - (3 of 4 people)
Intuniv:
  • female: 33.0% - (1 of 3 people)
  • male: 25.0% - (1 of 4 people)

Drug effectiveness by age:

Neurontin:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 100.0% - (1 of 1 people)
  • 30-39: 0.0% - (0 of 0 people)
  • 40-49: 66.0% - (2 of 3 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 100.0% - (1 of 1 people)
Intuniv:
  • 0-1: 0.0% - (0 of 0 people)
  • 2-9: 0.0% - (0 of 0 people)
  • 10-19: 100.0% - (1 of 1 people)
  • 20-29: 0.0% - (0 of 1 people)
  • 30-39: 100.0% - (1 of 1 people)
  • 40-49: 0.0% - (0 of 3 people)
  • 50-59: 0.0% - (0 of 0 people)
  • 60+: 0.0% - (0 of 1 people)

Most common drug interactions over time *:

< 1 month:
  • depressed level of consciousness
  • diarrhoea
  • fall
  • neuralgia
  • sinusitis
  • sleepiness - during the day
6 - 12 months:
  • tardive dyskinesia
  • weight decreased
  • blood thyroid stimulating hormone decreased
  • extrapyramidal disorder
1 - 2 years:
  • gingivitis
  • macular hole
  • neuropathy - peripheral
2 - 5 years:
  • depression
  • gingivitis
  • macular hole
  • neuropathy - peripheral
5 - 10 years:
  • sleepiness - during the day
not specified:
  • progressive multifocal leukoencephalopathy
  • nausea
  • vomiting
  • dizziness
  • drug ineffective
  • pain
  • anxiety
  • agitation
  • depression
  • fall

Most common drug interactions by gender *:

female:
  • progressive multifocal leukoencephalopathy
  • nausea
  • vomiting
  • anxiety
  • dizziness
  • diarrhoea
  • hallucination
  • pain
  • blood creatinine increased
  • blood urea increased
male:
  • progressive multifocal leukoencephalopathy
  • agitation
  • priapism
  • rash
  • cough
  • decreased appetite
  • weight decreased
  • drug ineffective
  • sedation
  • tardive dyskinesia

Most common drug interactions by age *:

2-9:
  • blood creatinine increased
  • blood urea increased
  • hypotension
  • pharyngitis streptococcal
  • pyrexia
  • renal failure acute
  • serum ferritin increased
  • urinary tract infection
  • urosepsis
  • vomiting
10-19:
  • weight decreased
  • agitation
  • abnormal behaviour
  • affective disorder
  • aggression
  • anhedonia
  • bipolar i disorder
  • crying
  • decreased appetite
  • depressed mood
20-29:
  • progressive multifocal leukoencephalopathy
  • blood glucose increased
  • death
  • nausea
  • abasia
  • anhedonia
  • anxiety
  • blood cholesterol decreased
  • cholecystitis chronic
  • cholelithiasis
30-39:
  • complex regional pain syndrome
  • dizziness
  • fall
  • loss of consciousness
  • nervous system disorder
  • paraesthesia oral
  • parotid gland enlargement
  • stevens-johnson syndrome
  • visual impairment
40-49:
  • dizziness
  • pain
  • nausea
  • cough
  • decreased appetite
  • dysphagia
  • dystonia
  • ear pain
  • fall
  • headache
50-59:
  • drug ineffective
  • palpitations
  • anxiety
  • nausea
  • postmenopausal haemorrhage
  • adverse event
  • dizziness
  • agitation
  • akathisia
  • blood pressure decreased
60+:
  • progressive multifocal leukoencephalopathy
  • dyspnoea
  • hallucination
  • cough
  • rash
  • back pain
  • skin ulcer
  • angina pectoris
  • constipation
  • nausea

* Approximation only. Some reports may have incomplete information.

How to use the study: print a copy of the study and bring it to your health teams to ensure drug risks and benefits are fully discussed and understood.

Do you take Neurontin and Intuniv?

Can you answer these questions?

More questions for: Neurontin, Intuniv

You may be interested in these reviews

More reviews for: Neurontin, Intuniv

On eHealthMe, Neurontin (gabapentin) is often used to treat pain. Intuniv (guanfacine hydrochloride) is often used to treat attention deficit hyperactivity disorder. Find out below the conditions the drugs are used for and how effective they are.

What is the drug used for and how effecitve is it:


NOTE: The study is based on active ingredients and brand name. Other drugs that have the same active ingredients (e.g. generic drugs) are NOT considered.

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

You may report adverse side effects to the FDA at http://www.fda.gov/medwatch/ or 1-800-FDA-1088 (1-800-332-1088).

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.